

# Lirilumab ELISA Kit

## Summary

---

<b>Catalog No.</b>	KDE43401
<b>Alternative Names</b>	BMS-986015, IPH2102, CAS: 1000676-41-4
<b>Stability and Storage</b>	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
<b>Detection method</b>	Colorimetric
<b>Sample type</b>	Plasma, Serum
<b>Assay type</b>	Quantitative
<b>Sensitivity</b>	0.156 µg/ml
<b>Range</b>	0.31-5 µg/mL
<b>Recovery</b>	80-120%
<b>Shipping</b>	2-8 °C
<b>Note</b>	For Research Use Only.

## Background

---

Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PRECOG LLC.

## Precision

---

CV<20%

## Data Image

---